Results 131 to 140 of about 1,472 (172)
Some of the next articles are maybe not open access.
Omadacycline: A New Tetracycline Antibiotic
Annals of Pharmacotherapy, 2018Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosage, and administration of omadacycline, a new tetracycline antibiotic. Data Sources: A literature search through PubMed, Google Scholar, and clinicaltrials.gov was conducted (2008 to October 2018) using the search ...
Dougherty, John A. +3 more
openaire +2 more sources
Omadacycline: First Global Approval
Drugs, 2018Paratek Pharmaceuticals are developing omadacycline (NUZYRA™), a first-in-class orally active aminomethylcycline antibacterial, as a treatment for various bacterial infections. The drug, which is available in intravenous and oral formulations, has a broad spectrum of antibacterial activity and was recently approved in the USA as a treatment for the ...
Anthony, Markham, Susan J, Keam
openaire +2 more sources
Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence
The Journal of Family Practice, 2022Given the growing prevalence of antibiotic resistance globally, there is an urgent need for new therapy options that are effective and well tolerated for treatment of common infections such as bacterial skin infections and pneumonia. Here, we summarize the findings of 3 phase 3 clinical trials of omadacycline, a novel tetracycline-derived ...
Steve, Vacalis +2 more
openaire +2 more sources
Omadacycline — The Newest Tetracycline
New England Journal of Medicine, 2019Omadacycline was the second antibiotic of the tetracycline class to be approved by the Food and Drug Administration (FDA) in 2018.
openaire +2 more sources
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics
Clinical Pharmacokinetics, 2019Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). Omadacycline has had chemical structure modifications at the C9 and C7 positions of the core tetracycline rings that allow stability in the efflux pump and ribosomal protection protein mechanisms of tetracycline resistance. The systemic exposure (i.e., maximum plasma concentrations [
Keith A. Rodvold +3 more
openaire +2 more sources
The role of omadacycline in skin and soft tissue infections
Current Opinion in Infectious Diseases, 2018Purpose of review Skin and soft tissue infections (SSTIs) are among the most frequent infections, contributing to significant morbidity and healthcare costs. Although numerous antibiotics are available for this indication, several medical needs remain unmet, especially for treating methicillin-resistant Staphylococcus aureus ...
Philippe, Montravers +2 more
openaire +2 more sources
Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial
Drugs of Today, 2018Omadacycline is a novel aminomethylcycline antimicrobial agent that is available in both oral and intravenous formulations. The distinguishing structural characteristics of omadacycline from other tetracyclines allow for its continued antimicrobial activity in the presence of traditional tetracycline resistance mechanisms (efflux pumps and ribosomal ...
J C, Cho +3 more
openaire +2 more sources
Omadacycline for the treatment of skin and soft tissue infections
Current Opinion in Infectious DiseasesPurpose of review To evaluate the current evidence on the use of omadacycline for the treatment of skin and soft tissue infections (SSTIs). Recent findings This narrative review examines the available data on the pharmacology, clinical efficacy, safety profile, and comparative ...
Vena, Antonio +4 more
openaire +2 more sources